アラバマ州における急性骨髄性白血病の臨床試験
アラバマ州内の拠点で、急性骨髄性白血病に関する21件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
被験者募集中第1相
21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- University of Alabama - Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Alabama Birmingham, Birmingham
被験者募集中第2/3相
18歳〜80歳 · 全性別 · 2026/08/05更新 · NCT06788756A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
被験者募集中
60歳以上 · 全性別 · 2026/07/06更新 · NCT06697600A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/03/04更新 · NCT07044544CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- University of Alabama O'Neal Cancer Center, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/16更新 · NCT05143996HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
被験者募集中観察研究
12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- The Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/08/26更新 · NCT03850574Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Alabama - Birmingham, Birmingham
被験者募集中健康なボランティア歓迎
18歳〜120歳 · 全性別 · 2025/07/25更新 · NCT05237258Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。